TY - JOUR T1 - Phosphodiesterase-5 inhibitors as novel cardioprotective agents: have we reached threshold for large-scale clinical trials? JF - Heart JO - Heart SP - 1745 LP - 1745 DO - 10.1136/heartjnl-2017-311788 VL - 103 IS - 21 AU - David Charles Hutchings AU - Simon George Anderson AU - Andrew W Trafford Y1 - 2017/11/01 UR - http://heart.bmj.com/content/103/21/1745.abstract N2 - We read with great interest the compelling findings of Andersson et al demonstrating strong association between on-demand use of phosphodiesterase-5 (PDE5) inhibitors (PDE5is) and a reduction in cardiovascular mortality and heart failure hospitalisation in patients followed up following their first myocardial infarction (MI). We previously reported in Heart a similarly strong association between PDE5i use and reduced mortality in a cohort of patients with type 2 diabetes and attendant high cardiovascular risk.1 In our study, we showed that the association was stronger in patients with prior MI, supporting a cardioprotective action, although we were unable to … ER -